Roivant Sciences EPS (Diluted) decreased by 123.5% to $-0.38 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 265.2%, from $0.23 to $-0.38. Over 3 years (FY 2021 to FY 2024), EPS (Diluted) shows an upward trend with a -41.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$0.13 | -$0.32 | -$0.41 | -$0.39 | -$0.48 | -$0.42 | -$0.49 | -$0.03 | -$0.38 | -$0.40 | $6.03 | $0.00 | $0.12 | -$0.31 | $0.23 | -$0.29 | -$0.33 | -$0.17 | -$0.38 |
| QoQ Change | — | -146.2% | -28.1% | +4.9% | -23.1% | +12.5% | -16.7% | +93.9% | <-999% | -5.3% | >999% | -100.0% | — | -358.3% | +174.2% | -226.1% | -13.8% | +48.5% | -123.5% |
| YoY Change | — | — | — | — | -269.2% | -31.2% | -19.5% | +92.3% | +20.8% | +4.8% | >999% | +100.0% | +131.6% | +22.5% | -96.2% | — | -375.0% | +45.2% | -265.2% |